LEWISVILLE, TX, United States

Bio-Synthesis, Inc.

www.biosyn.com/
LEWISVILLE, TX, United States

Bio-Synthesis, Inc. is a biotechnology company headquartered in Lewisville, Texas. It is a provider of custom and catalog peptides, custom oligos, antibodies, organic synthesis, and analytical services. Biomedical researchers worldwide in universities, biotech companies, private clinics, and government agencies use products from Bio-Synthesis, Inc. in studies ranging from PCR diagnostics to cancer research and the Human Genome Project.The DNA Identity Testing Center, a subsidiary of Bio-Synthesis, Inc. , works with private citizens, legal representatives, and law enforcement providing services in personal and legal paternity tests, family relationship DNA tests, immigration DNA tests, forensic DNA tests, ancestry DNA tests, and identity DNA tests. Wikipedia.


Time filter

Source Type

Pop L.M.,Cancer Immunobiology Center | Pop L.M.,University of Texas Southwestern Medical Center | Barman S.,Hamon Center for Therapeutic Oncology Research | Barman S.,University of Texas Southwestern Medical Center | And 20 more authors.
Cancer Research | Year: 2014

CD22 is a transmembrane glycoprotein expressed by mature B cells. It inhibits signal transduction by the B-cell receptor and its coreceptor CD19. Recent reports indicate that most human lung cancer cells and cell lines express CD22, making it an important new therapeutic target for lung cancer. The objective of our studies was to independently validate these results with the goal of testing the efficacy of our CD22 immunotoxins on lung cancer cell lines. As determined by quantitative real-time PCR analysis, we found that levels of CD22 mRNA in a panel of human lung cancer cell lines were 200 to 60,000-fold lower than those observed in the human CD22+ Burkitt lymphoma cells, Daudi. Using flow cytometry with a panel of CD22 monoclonal antibodies and Western blot analyses, we could not detect surface or intracellular expression of CD22 protein in a panel of lung cancer cell lines. In addition, the in vitro proliferation of the lung tumor cell lines was not affected by either CD22 antibodies or our highly potent anti-CD22 immunotoxin. In contrast, CD22 + Daudi cells expressed high levels of CD22mRNA and protein, and were sensitive to our CD22 immunotoxin. Importantly, primary non-small cell lung cancers from more than 250 patient specimens did not express detectable levels of CD22 protein as assessed by immunohistochemistry. We conclude that CD22 is not expressed at measurable levels on the surface of lung cancer cells, and that these cells cannot be killed by anti-CD22 immunotoxins. © 2014 American Association for Cancer Research.


Kim S.-K.,Northeastern State University | Castro A.,Bio-Synthesis, Inc. | Kim E.S.,Bio-Synthesis, Inc. | Dinkel A.P.,Northeastern State University | And 2 more authors.
PLoS ONE | Year: 2016

Modified nucleosides have the potential to inhibit DNA polymerases for the treatment of viral infections and cancer. With the hope of developing potent drug candidates by the modification of the 2′,4′-position of the ribose with the inclusion of a bridge, efforts were focused on the inhibition of Taq DNA polymerase using quantitative real time PCR, and the results revealed the significant inhibitory effects of 2′,4′-bridged thymidine nucleoside on the polymerase. Study on the mode of inhibition revealed the competitive mechanism with which the 2′,4′-bridged thymidine operates. With a Ki value of 9.7 ± 1.1 μM, the 2′,4′-bridged thymidine proved to be a very promising inhibitor. Additionally, docking analysis showed that all the nucleosides including 2′,4′-bridged thymidine were able to dock in the active site, indicating that the substrate analogs reflect a structural complementarity to the enzyme active site. The analysis also provided evidence that Asp610 was a key binding site for 2′,4′- bridged thymidine. Molecular dynamics (MD) simulations were performed to further understand the conformational variations of the binding. The root-mean-square deviation (RMSD) values for the peptide backbone of the enzyme and the nitrogenous base of the inhibitor stabilized within 0.8 and 0.2 ns, respectively. Furthermore, the MD analysis indicates substantial conformational change in the ligand (inhibitor) as the nitrogenous base rotated anticlockwise with respect to the sugar moiety, complemented by the formation of several new hydrogen bonds where Arg587 served as a pivot axis for binding formation. In conclusion, the active site inhibition of Taq DNA polymerase by 2′,4′-bridged thymidine suggests the potential of bridged nucleosides as drug candidates. © 2016 Kim et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


PubMed | Bio-Synthesis, Inc. and Northeastern State University
Type: Journal Article | Journal: PloS one | Year: 2016

Modified nucleosides have the potential to inhibit DNA polymerases for the treatment of viral infections and cancer. With the hope of developing potent drug candidates by the modification of the 2,4-position of the ribose with the inclusion of a bridge, efforts were focused on the inhibition of Taq DNA polymerase using quantitative real time PCR, and the results revealed the significant inhibitory effects of 2,4-bridged thymidine nucleoside on the polymerase. Study on the mode of inhibition revealed the competitive mechanism with which the 2,4-bridged thymidine operates. With a Ki value of 9.7 1.1 M, the 2,4-bridged thymidine proved to be a very promising inhibitor. Additionally, docking analysis showed that all the nucleosides including 2,4-bridged thymidine were able to dock in the active site, indicating that the substrate analogs reflect a structural complementarity to the enzyme active site. The analysis also provided evidence that Asp610 was a key binding site for 2,4-bridged thymidine. Molecular dynamics (MD) simulations were performed to further understand the conformational variations of the binding. The root-mean-square deviation (RMSD) values for the peptide backbone of the enzyme and the nitrogenous base of the inhibitor stabilized within 0.8 and 0.2 ns, respectively. Furthermore, the MD analysis indicates substantial conformational change in the ligand (inhibitor) as the nitrogenous base rotated anticlockwise with respect to the sugar moiety, complemented by the formation of several new hydrogen bonds where Arg587 served as a pivot axis for binding formation. In conclusion, the active site inhibition of Taq DNA polymerase by 2,4-bridged thymidine suggests the potential of bridged nucleosides as drug candidates.


Trademark
Bio-Synthesis, Inc. | Date: 2011-03-08

A synthetic oligonucleotide for scientific or research use.


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 590.21K | Year: 2010

DESCRIPTION (provided by applicant): The objective is to develop a glycoside adjuvant or immune agonist carrying the chemical structures needed to concurrently stimulate in a cooperative manner both innate and adaptive immunities, leading to a synergistic effect on the cellular (Th1) and humoral (Th2) immunities. It is likely that these adjuvants would also stimulate strong mucosal immunity. Studies with HIV-1 model vaccines indicate that a favorable immune protection would entail besides cytotoxic T lymphocytes (CTL), neutralizing antibodies and mucosal immunity. Yet, HIV's vast capacity to mutate may allow its escape from immune control. That HIV up regulates the CD4+ T cells' expression of the inhibitory CTLA-4 receptor, blocking the co-stimulatory ligands B7-1/B7-2 (CD80/CD86) expressed by antigen presenting cells (APCs) and required for T cell activation, means an anergic immune system that would not protect against the virus. Thus, HIV-1 vaccines would demand superior adjuvants to raise the immune response to levels not required before. The synergistic effects of the concerted stimulation of various receptors for innate and acquired immunity, deliver a much higher immune response with antigen and DNA based vaccines. The strategy to develop these adjuvants involves replacing in glycosides with aldehyde- carrying triterpenes their i) natural carbohydrate moieties with oligosaccharides that are ligands of innate immunity receptors, e.g. toll-like receptors (TLRs) and lectins, and ii) hydrophobic acyl group with new lipophilic chains, that may be design to serve as ligands for innate immunity receptors. The aldehyde group by forming imines with the amino groups of certain cell surface receptor(s) provides an alternative co-stimulatory signal needed to elicit Th1/Th2 immunity while the newly added innate immunity ligand, i.e. oligosaccharides and/or lipids, by binding to certain receptors would stimulate innate immunity. The triterpene group plays a role in the delivery of exogenous antigens directly into the cell's cytosol for processing by the endogenous pathway and CTL production, thus avoiding the need for viral vectors and production of interfering antibodies. Result of the concurrent stimulation of the receptors for both adaptive and innate immunities located on the same cell would be a synergistic effect on the immune response; i.e., the response stimulated by this immune agonist would be much higher than the aggregate of the responses elicited by the individual ligands. Phase I Specific Aims are, 1) Synthesize i) an immune agonist, having an aldehyde-carrying triterpene linked covalently to a mannan oligosaccharide and a myristoyl lipophilic chain, and ii) the controls lacking either the oligosaccharide chain or aldehyde; and 2) Study the role of this new adjuvant in i) the activation of DCs and macrophages by studying up-regulation of MHC, co-stimulatory molecules, and increased secretion of pro-inflammatory cytokines, ii) activating a protective immunity in vivo against a pathogen, by evaluating antigen specific CD4, CD8 responses, antigen specific antibodies, and protection against infection in the mouse model. The immune responses would be compared to that stimulated by well-known innate immunity ligands. PUBLIC HEALTH RELEVANCE: Results of this research would allow enhancing Th1and Th2 immunities with production of CTLs as well as antibodies with high avidity. As these compounds should stimulate mucosal immunity, they would provide a first line of defense against HIV-1 infection. They should also allow the improvement of vaccines' efficacy in the elderly population, which because of immune senescence, frequently shows some immune deficiencies, that interferes with the stimulation of an effective immunity. These agonists' capacity to deliver a co-stimulatory signal that is independent of the CD80/86 ligands may have applications in HIV-1 therapeutic vaccines where the CTLA-4 inhibitory receptor blocks the activity of the natural ligands leading to anergy.


Bio-Synthesis, Inc. | Entity website

Welcome to our Tech Lounge! This is a place where you can find answers, ask questions, and explore molecular and analysis tools for your life science research


Bio-Synthesis, Inc. | Entity website

The amount of product theoretically possible from any particular synthesis is determined by the quality of the synthesis itself, generally done on an automated synthesizer. The coupling efficiency of the synthesis is very important ...


Conjugating oligos, peptides, antibodies, proteins, enzymes,. drug, solid support attachment ...


Bio-Synthesis, Inc. | Entity website

Loading Bio-Synthesis, Inc. collaborators
Loading Bio-Synthesis, Inc. collaborators